WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to Senior Vice President of Market Access. Mr. Kelly succeeds David Snow who served as the Company's Chief Commercial Officer since 2015 and is leaving Radius.
"The appointment of Mr. Kelly and promotion of Ms. Mott will help drive the execution of our sales and marketing strategy to best position TYMLOS™ for market leadership. Mr. Kelly's experience combines a proven track record of successfully growing sales while carefully listening to customers' needs which fits perfectly with Radius' focus on innovation, quality product delivery, and rapid expansion," said Jesper Høiland, President and Chief Executive Officer of Radius Health. "Throughout his leadership roles at Novo Nordisk, Mr. Kelly has been recognized for achieving rapid and sustained growth in both turnaround and deeply competitive markets. His drive and experience will be invaluable in guiding Radius through this next period of accelerated growth."
"The Board and I want to thank David Snow for his contributions to Radius, which were instrumental in driving the launch of TYMLOS, and positioned the Company for an important stage of growth. We will build on our successful track record of quality and reliability to advance our portfolio in the market," continued Mr. Høiland.
Mr. Kelly commented, "I am excited to be joining Radius during the early stage of commercialization of TYMLOS and leading its continued commercial expansion. I look forward to working with senior management and the entire organization on executing a successful commercial strategy and delivering on the Company's key mission to develop and commercialize innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases."
Mr. Kelly brings 20 years of pharmaceutical industry sales and marketing experience, including performance-driven sales leadership that outpaced goals in billion-dollar sales regions. During his time at Novo Nordisk, Joe increased year over year performance to consistently rank #1 company-wide. He has earned more than twelve professional awards and six promotions, including a nine-time winner of Circle of Excellence, Novo Nordisk's most prestigious sales award, and been a three-time recipient of the Vision Award for leadership.
Commenting on the promotion of Ms. Mott, Mr. Høiland said, "With more than 25 years of industry experience, Ms. Mott has demonstrated tremendous knowledge of the payer landscape and expertise in setting and executing on our market access strategy. Through the efforts of Amanda and her team, TYMLOS is now covered by approximately 87% of commercial and 35% of Medicare plans. We are confident that Amanda and her team will continue to strengthen our payer relations and elevate the strategic value provided by market access."
Prior to joining Radius, Ms. Mott led market strategy teams for Amgen's portfolio of 15 products and six new product/indication launches, and led her AstraZeneca Payer team to be twice ranked the No. 1 Managed Markets Account Executive Team in the Industry by Health Industries Research Companies (HIRC). She has received AstraZeneca Global Commercial Leadership and President's Model of Excellence Awards and the Healthcare Businesswomen's Association Rising Star Award. She is also a Fellow of the International Women's Forum, which is dedicated to building better global leadership across careers, continents and cultures by connecting the world's most pre-eminent women of significant and diverse achievements.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer, and vasomotor symptoms in postmenopausal women; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the progress of abaloparatide-SC in the regulatory process with the EMA, our expectations regarding commercialization of TYMLOS in the U.S. and company growth, the progress in the development of our product candidates, including abaloparatide-TD, elacestrant (RAD1901) and RAD140, and the potential clinical uses and therapeutic and other benefits of our product candidates, including abaloparatide-TD, elacestrant and RAD140.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we expect to need to raise additional funding, which may not be available; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products and any collaboration agreements failing to be successful; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period ending June 30, 2017 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor & Media Relations Contact: